Author: Janine Anthes

This year’s Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, the leading research and educational conference for MS healthcare professionals in North America, kicks off tomorrow, October 25 through October...

 Findings presented at ECTRIMS 2021 suggest that deep, persistent B-cell depletion is linked to reduced disease activity Results from a new analysis of the inebilizumab pivotal Phase 2/3 N-MOmentum trial were presented this year...

Data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS) will be highlighted at the upcoming 37th Congress of the European Committee for Treatment and...

A total of 10 Janssen-sponsored data abstracts on MS research will be presented at the 2021 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) virtual congress from October 13 to 15, in Vienna,...

Check Out the New Interactive Program ePoster Tours This year’s ECTRIMS we will have 8 poster tours that will highlight the top scored ePoster. All top scored ePoster authors have been contacted. Poster Tour 1 – Clinical:...

The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Vienna is the world’s largest annual international conference devoted to basic and clinical research in multiple...

New data on inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) will be presented at the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2021, Oct. 13-15....

New data on ocrelizumab and satralizumab-mwge will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from October 13 – 15, 2021. These data include 38...

Coming soon…

Coming soon…

Coming soon…

Data from the INFINITY clinical trial of ADVM-022 in patients with diabetic macular edema (DME) during the American Society of Retina Specialists (ASRS) 39th Annual Scientific Meeting and will be presented an encore presentation...

Positive phase 1 and 2 findings support an ongoing efficacy assessment of the Ref-1 inhibitor for diabetic retinopathy and diabetic macular edema. Investigative oral drug APX3330 has been associated with generally favorable...

Findings from a Phase 1/2a clinical trial of its Multi-Characteristic Opsin (MCO) gene therapy for people blinded by retinitis pigmentosa (RP) were highlighted in two presentations during the 2021 Annual Meeting of the American...

Initial data from the ongoing Phase II ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery was...

Interim safety and clinical activity data from the Phase 1/2 clinical trial of intravitreal 4D-125 in patients with advanced X-linked retinitis pigmentosa (XLRP) was presented in a late-breaking presentation at the American...

Phase 1/2a clinical trial of its Multi-Characteristic Opsin (MCO) gene therapy for people blinded by retinitis pigmentosa (RP) will be highlighted in two presentations during the 2021 Annual Meeting of the American Society of...

The American Society of Retina Specialists (ASRS) will host its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas. According to ASRS, its...

The American Society of Retina Specialists (ASRS) will host its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas. ASRS 2021 serves to...